To redirect T cells against tumor cells, T cells can be engineered ex vivo to express cancer-
antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T …

The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …

Adoptive cell transfer (ACT) using chimeric antigen receptor (CAR)‐modified T cells can
induce durable remissions in patients with refractory B‐lymphoid cancers. By contrast …

Adoptive cell therapy (ACT) has seen a steep rise of new therapeutic approaches in its
immune-oncology pipeline over the last years. This is in great part due to the recent …

Therapeutic T cells with desired specificity can be engineered by introducing T-cell
receptors (TCRs) specific for antigens of interest, such as those from pathogens or tumour …

T cell receptor (TCR) ligand discovery is essential for understanding and manipulating
immune responses to tumors. We developed a cell-based selection platform for TCR ligand …

Bispecific antibodies have recently gained major interest as they allow novel mechanisms-of-
action and/or therapeutic applications that cannot be achieved using conventional IgG …

Simple Summary The aging of the world population leads to a constant increase of cancer-
related morbidity and mortality. Treatment of late-stage tumors has become a significant …

Immunotherapy of cancer has made tremendous progress in recent years, as demonstrated
by the remarkable clinical responses obtained from adoptive cell transfer (ACT) of patient …

Adoptive T cell therapy (ACT) is a rapidly evolving therapeutic approach designed to
harness T cell specificity and function to fight diseases. Based on the evidence that T …